Mineralys Therapeutics, Inc. (MLYS)

Mineralys Therapeutics' stock decreased by 18.6% in the first half of 2026, but showed a significant increase of 102.49% compared to the previous year. Key events included the release of Q1 2026 financial results, the FDA's acceptance of the NDA for lorundrostat, and the exploratory Phase 2 OSA trial results. Insider trading activity showed net buying, although some insiders executed pre-arranged sales. TD Cowen initiated coverage with a "Buy" rating, and the company has a consensus rating of "Moderate Buy" from analysts.

Mineralys Therapeutics is developing drugs for chronic conditions, so the demand for lorundrostat, if approved, is unlikely to be seasonal. Demand would likely be steady and driven by the prevalence of these chronic diseases and the drug's efficacy and market adoption. The company is currently in the pre-revenue stage, focusing on clinical development and regulatory activities, with a potential U.S. market launch by late 2026.

Mineralys Therapeutics, Inc. (MLYS) is a clinical-stage biopharmaceutical company focused on developing medicines for diseases driven by elevated aldosterone. The company's primary product candidate is lorundrostat, an orally administered aldosterone synthase inhibitor, being developed for cardiorenal conditions like hypertension, chronic kidney disease, and obstructive sleep apnea.

Mineralys Therapeutics, Inc. is headquartered in Radnor, Pennsylvania, United States, and focuses on developing medicines for the United States market.

Mineralys Therapeutics has maintained a generally positive brand reputation, with a consensus rating of "Moderate Buy" from analysts. However, the missed primary endpoint in the OSA trial led to a downgrade by one analyst, and competitive pressures from companies like AstraZeneca pose a risk. The FDA's acceptance of the NDA for lorundrostat has largely supported a favorable view of the company.

Mineralys Therapeutics, Inc. has significant institutional ownership, with institutions holding 84.46% of the stock and individual insiders holding 18.94%. Major institutional owners include Catalys Pacific, LLC, RA Capital Management, L.P., and BlackRock, Inc. Srinivas Akkaraju is the largest individual shareholder, owning 14.73% of the company.